Age-Less Energy: The Real Science of SS-31 | Age-Less Top 20 Peptides

SS-31 — also known as elamipretide — occupies a category no other compound in this series can claim: it is the first mitochondria-targeted therapy ever to receive FDA approval. In this episode, Dr. Ethan traces the compound from its accidental discovery in a Weill Cornell pharmacology lab through to its September 2025 accelerated approval for Barth syndrome, unpacking the biology of cardiolipin — the inner mitochondrial membrane phospholipid whose decline with age sits at the centre of SS-31's entire mechanistic rationale — and explaining precisely why a peptide that concentrates over 1,000-fold inside the mitochondrial membrane represents a genuinely novel class of therapeutic tool. The mechanism is well-supported, the preclinical literature is large and independently replicated, and the clinical trial programme is the most rigorous of any compound covered in this series so far.

The honest picture is more nuanced than the approval alone would suggest. The regulatory journey was long and difficult — an initial refusal to file, a subsequent rejection, and an eventual accelerated approval based on an intermediate endpoint in a rare paediatric disease population. The heart failure and AMD programmes remain in active development, not yet approved. And for the application most longevity-focused listeners are actually interested in — preserving mitochondrial function in a healthy ageing adult — there are no completed trials and no approved protocols. Dr. Ethan draws a precise line between what the approval actually means, what the active trial pipeline shows, and where the extrapolation to healthy ageing begins — and explains why SS-31 is simultaneously the most clinically credible mitochondrial compound in the longevity space and still some distance from a validated longevity intervention.